IP Library › Granted Patent US 8,916,172
Granted Patent B2
US 8,916,172 · App. 12/987,791 · Granted Dec 23, 2014

MVA expressing modified HIV envelope, gag, and pol genes

Inventors: Bernard Moss (Bethesda, MD); Linda Wyatt (Rockville, MD); Patricia Earl (Chevy Chase, MD); Harriet L. Robinson (Atlanta, GA)
Assignees: Emory University; National Institute of Allergy and Infectious Diseases (NIAID); The United States of America, as represented by the Department of Health and Human Services
C12N15/86A61K2039/525C12N2830/15C12N2830/60C12N2740/16222C12N2710/24143A61K39/21A61K2039/57C12N2710/24171A61K2039/53C07K14/005C12N2830/00C12N2740/15022C12N2740/16122
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,172
App. No.
12/987,791
Granted
Dec 23, 2014
Kind
B2
Abstract

The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.

Claims (4)

1. A recombinant MVA virus expressing HIV-1 Gag, HIV-1 Pol lacking the integrase domain wherein the HIV-1 Pol expressed by the recombinant MVA virus has at least one amino acid change that inhibits reverse transcriptase activity, at least one amino acid change that inhibits strand transfer activity and at least one amino acid change that inhibits RNaseH activity, and at least the gp120 protein and the membrane-spanning domain and ectodomain of gp41 protein of HIV-I Env, but lacking at least 115 amino acids of the cytoplasmic domain of gp41 protein.

2. A recombinant MVA virus that expresses the HXB2 Gag/Pol of MVA 48 encoded by SEQ ID NO:5 and the truncated ADA envelope of MVA 48 encoded by SEQ ID NO:3.

3. A pharmaceutical composition comprising the recombinant MVA of claim 1 or claim 2 and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising the recombinant MVA of claim 2 and a pharmaceutically acceptable carrier.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2014
From: MOSS, BERNARD; WYATT, LINDA S.; EARL, PATRICIA L.
To: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 033117/0260 →
CORRECT CONVEYANCE TO SHOW EXECUTIVE ORDER 9424, AT REEL 026512, FRAME 0404. Recorded Oct 11, 2013
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPART. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031485/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2011
From: ROBINSON, HARRIET L.
To: EMORY UNIVERSITY
Reel/Frame 026512/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2011
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026512/0404 →
Continuity (5)
Continuation 12018150 · Jan 22, 2008
Continuation 10646628 · Aug 22, 2003
Continuation PCTUS0206713 · Mar 1, 2002
Provisional Application 60274434 · Mar 8, 2001
Related Publication 20110104199A1 · May 5, 2011